Some of you know I've been hounding the Department of Health for an answer for over a month now. I asked them one simple question: What is the benefit of Seroxat?
In classic MHRA/GlaxoSmithKline style they answer me - totally avoiding the question:
----- Original Message -----
From: dhmail@dh.gsi.gov.uk
To: fiddaman64
Sent: Tuesday, March 04, 2008 2:29 PM
Subject: Response to your Query : - Ref:DE00000283875 - Anti-depressants
Our ref: REDACTED
Dear Mr Fiddaman,
Thank you for your email of 26 February to the Department of Health about a recently published study on antidepressants. New guidance on the treatment of depression will be issued by National Institute for Health and Clinical Excellence later in the year, and this new study will be considered as the guidance is prepared. Until then, the message to patients and doctors remains the same - antidepressants are an appropriate treatment for moderate or severe depression.
The Department is, however, expanding the availability of psychological therapies as an alternative to drugs with extra investment and plans to train an extra 3,600 psychological therapists. The evidence shows that these therapies are effective and often preferred by patients.
I hope this reply is helpful.
Yours sincerely,
Edward Corbett
Customer Service Centre.
----
I hope this reply is helpful?
Yup, about as helpful as sending me a man with no arms to groom my dog!
So, what is the benefit of Seroxat? I may go and ask the brick wall at the foot of my garden!
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
By Bob Fiddaman
ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING
AVAILABLE FOR DOWNLOAD HERE
PAPERBACK COMING SOON
"It's not about what they tell you, it's about what they don't."
~ Bob Fiddaman, Author, Blogger, Researcher, Recipient of two Human Rights awards
Researching drug company and regulatory malfeasance for over 16 years
Humanist, humorist
Subscribe to:
Post Comments (Atom)
Please contact me if you would like a guest post considered for publication on my blog.
3 comments: